APEX1 and eye disorder: Given the importance of the redox-regulated transcriptional control by APE1/Ref-1 in neovascular eye disease, modulating this function may make APE1/Ref-1 redox inhibitors potential candidates for treating diseases such as nvAMD, PDR/DME and ROP.